L&S Knock-Out AYJ 11.06.2024/ DE000LX3ZFK6 /
| 2024-05-23 12:43:35 PM | Chg.+0.04 | Bid12:43:35 PM | Ask12:43:35 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 1.95EUR | +2.09% | 1.95 Bid Size: - |
2.00 Ask Size: - |
VALNEVA SE EO... | 2.25 EUR | 2024-06-11 | Call |
GlobeNewswire
05-13
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya...
GlobeNewswire
05-07
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
03-25
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
GlobeNewswire
03-21
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th Wo...
GlobeNewswire
03-20
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
GlobeNewswire
03-18
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and Orbi...
GlobeNewswire
03-04
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
GlobeNewswire
02-29
U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHI...
GlobeNewswire
01-10
Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine
GlobeNewswire
01-04
Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Foru...
GlobeNewswire
2023-12-04
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, ...
GlobeNewswire
2023-12-04
Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine ...
GlobeNewswire
2023-11-27
EMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assess...
GlobeNewswire
2023-11-15
Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including ...
GlobeNewswire
2023-11-13
Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chik...
GlobeNewswire
2023-11-10
Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ®
GlobeNewswire
2023-11-09
Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates
GlobeNewswire
2023-11-07
Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update
GlobeNewswire
2023-11-07
Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference
